Johnson & Johnsonreports Q4 2024 and Full-Year 2024 results Johnson & Johnson(NYSE: JNJ) today announced results for third-quarter 2024. January 21, 2025 SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression ...
Portfolio of Clinical and Preclinical Programs, Including Lead Product Candidate ARX517, a Prostate-Specific Membrane Antigen (PSMA)-Targeting Antibody Drug Conjugate (ADC), Strengthens Johnson & Johnson's Commitment to Oncology Innovation Novel Technolo
Johnson & Johnson (NYSE: JNJ), the world’s largest, most diversified healthcare products company, today announced it has completed its acquisition of Abiomed, Inc. Abiomed is now part of Johnson & Johnson and will operate as a standalone business within
including the development of critical antiretroviral treatments and HIV prevention tools, yet the disease remains one of the greatest global health threats of our time. An estimated 37 million people are currently living with HIV-1 globally, and nearly 2 million people become newly infected each yea...
and Johnson & Johnson enterprise revenue growth. Johnson & Johnson expects the transaction to be slightly dilutive to neutral to adjusted earnings per share in the first year, considering the impact of financing, and then accretive by approximately $0.05 in 2024, and increasingly accretive thereafter...
NEW BRUNSWICK, New Jersey, March 16, 2018 /PRNewswire/ -- Johnson & Johnson Announces Binding Offer from Platinum Equity to Acquire LifeScan, Inc.
"The fourth quarter of 2017 was higher than (the guidance), as you pointed out, and I think this just has to do with the ramp of products, particularly in the pharmaceutical business, which are continuing to grow, but they're obviously continuing to grow now off of a higher base," Car...
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding the potential transaction between Johnson & Johnson and Actelion Ltd. The reader is cautioned not to rely on these forward-looking statemen...
The speaker will almost certainly need Democratic votes just to get the package to the floor, and the minority party has not signaled whether it will support him.
“We continuously evaluate and optimize our portfolio to best position the business for long-term growth,” the company said in a statement. “This transition will help simplify our product offerings, deliver sustainable innovation, and meet the needs of our consumers, customers and evolving g...